| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 10.1 | 15.4 | 9.1 |
| Other income | 4.6 | 1.5 | -0.1 |
| Total income | 14.7 | 16.9 | 9.0 |
| Profit before exceptional items & tax | 1.2 | 3.4 | 2.6 |
| Profit before tax | 1.2 | 3.4 | 2.6 |
| Net profit | 0.5 | 3.4 | 2.0 |
| Operating margin | 8.2% | 20.1% | 28.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -75.00% |
|---|---|
| Net profit, quarter on quarter | -85.30% |
| Revenue, year on year | +11.00% |
BSE results filing, BSE: 544445. Figures extracted from the filing.
Asston Pharmaceuticals Ltd: key numbers
- Share price
- ₹99.75
- Market cap
- ₹84.91 Cr
- Revenue (annual)
- ₹25.47 Cr
- Net profit (annual)
- ₹3.87 Cr
- P/E (TTM)
- 22.0×Sector 50.4×
- Promoter holding
- 50.66%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Asston Pharmaceuticals Ltd
All →Asston Pharmaceuticals Other Announcement
Asston Pharmaceuticals Ltd submitted its quarterly shareholding pattern disclosure, detailing the shareholding status of promoters and public shareholders for the period ended March 2026.
Asston Pharmaceuticals Annual Report
Asston Pharmaceuticals has submitted its 7th Annual Report for the financial year 2025-26. The report provides a comprehensive overview of the company's annual financial performance.
Asston Pharmaceuticals Annual General Meeting
Asston Pharmaceuticals Limited announced its Annual General Meeting scheduled for September 29, 2026. The agenda includes adopting financial statements, appointing auditors, and revising remuneration for key managerial personnel.
Asston Pharmaceuticals Capital Structure Change
Asston Pharmaceuticals allotted 24,10,431 equity shares at Rs. 115 per share via preferential allotment, raising Rs. 27.72 Crore. This increases the company's paid-up equity share capital.
- Value
- ₹27.72 Cr
Asston Pharmaceuticals Board Meeting Outcome
Asston Pharmaceuticals announced the outcome of its board meeting, including auditor appointments, director re-appointment, and upcoming AGM scheduling. The board also proposed remuneration increases for directors.